멀티 장기 칩 - 장기 멀티 조직 공 배양을위한 미세 유체 플랫폼

Executive Industry Relevance

Long-term multi-tissue coculture in a microfluidic platform addresses the critical need for predictive preclinical models that better capture organ-organ interactions and chronic substance exposure effects. By enabling stable, near-physiologic fluid flow and repeated dosing over 28 days, the system supports mechanistic de-risking in early discovery and improves translational confidence for hepatotoxicity and dermal safety assessment. This positions the technology as a reusable capability for lead identification and predictive modeling in pharmaceutical R&D pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of cross-tissue signaling pathways and mechanistic de-risking of compound-induced organ interactions.
• Operational Value: Supports functional validation of targets in a multicellular microenvironment that reflects physiological complexity.

Screening & Assay Development

• Scientific Value: Provides a standardized, reproducible platform for quantitative assessment of substance effects across interconnected tissue models.
• Operational Value: Enables scalable, long-term coculture with media perfusion for repeated compound exposure and readout collection.

Translational & Preclinical Research

• Scientific Value: Enhances disease relevance by modeling human liver-skin-vascular interactions in a controlled, perfused system.
• Operational Value: Supports continuity from discovery through preclinical evaluation by maintaining tissue functionality over extended culture periods.

Pipeline & Workflow Integration

The microfluidic multi-organ chip integrates into early discovery workflows by enabling hypothesis testing of organ-specific toxicities and pathway modulation in a human-relevant coculture system.

• Discovery Biology: Facilitates hypothesis testing of inter-organ communication and compound effects on tissue-specific functions.
• Screening: Delivers assay readiness through stable, perfused coculture conditions suitable for compound library screening.
• Analytics: Generates quantitative, time-resolved readouts from multiple tissue compartments to support comparative condition analysis.
• Translational Research: Promotes preclinical continuity by preserving organotypic architecture and function over 28-day culture periods.
• Enterprise Reuse: Offers a reusable perfusion platform adaptable to multiple tissue combinations and compound testing campaigns.

Operational & Enterprise Impact

• Scientific Value: Improves predictive confidence by reducing mechanistic ambiguity in organ-organ crosstalk and substance response.
• Operational Value: Ensures standardization, reproducibility, and scalability of long-term multicellular coculture under controlled flow.
• Strategic Value: Informs better go/no-go decisions by identifying organ-specific liabilities earlier, reducing late-stage attrition risk.
• Portfolio Impact: Enables risk-adjusted prioritization of candidates based on multi-tissue tolerance and functional readouts.

Implementation Considerations

• Requires expertise in microfluidic system operation, primary cell handling, and tissue model preparation.
• Depends on perfusion-compatible instrumentation, sterile fluid handling, and real-time monitoring infrastructure.
• Necessitates cross-team standardization of media formulations, flow rates, and sampling protocols for reproducible results.
• Involves adaptation considerations when integrating diverse primary tissues or biopsies with varying culture requirements.
• Limited by the need for specialized fabrication and validation of chip designs to maintain physiologic shear stress and volume ratios.

Biopharma FAQs